Ubelgiji - Kiingereza - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

baxter holding b.v. - tranexamic acid 500 mg/5 ml - solution for injection/infusion - 100 mg/ml - tranexamic acid 100 mg/ml - tranexamic acid

Ubelgiji - Kiingereza - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

baxter holding b.v. - tranexamic acid 500 mg/5 ml - solution for injection/infusion - 100 mg/ml - tranexamic acid 100 mg/ml - tranexamic acid

Kanada - Kiingereza - Health Canada

baxter corporation - tranexamic acid - solution - 500mg - tranexamic acid 500mg - hemostatics

Kanada - Kiingereza - Health Canada

baxter corporation - tranexamic acid - solution - 1000mg - tranexamic acid 1000mg - hemostatics

Marekani - Kiingereza - NLM (National Library of Medicine)

almaject, inc. - tranexamic acid (unii: 6t84r30kc1) (tranexamic acid - unii:6t84r30kc1) - tranexamic acid injection is indicated in patients with hemophilia for short-term use (2 to 8 days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. tranexamic acid injection is contraindicated: • in patients with subarachnoid hemorrhage. anecdotal experience indicates that cerebral edema and cerebral infarction may be caused by tranexamic acid injection in such patients. • in patients with active intravascular clotting [see warnings and precautions (5.1)]. • in patients with hypersensitivity to tranexamic acid or any of the ingredients [see warnings and precautions (5.4)]. risk summary available data from published studies, case series and case reports with tranexamic acid use in pregnant women in the second and third trimester and at the time of delivery have not clarified whether there is a drug-associated risk of miscarriage or adverse maternal or fetal outcomes. there are 2 (0.02%) infant cases with structural abnormalities that

Marekani - Kiingereza - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - tranexamic acid (unii: 6t84r30kc1) (tranexamic acid - unii:6t84r30kc1) - tranexamic acid injection is indicated in patients with hemophilia for short-term use (2 to 8 days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. tranexamic acid is contraindicated: in patients with subarachnoid hemorrhage. anecdotal experience indicates that cerebral edema and cerebral infarction may be caused by tranexamic acid in such patients. in patients with active intravascular clotting [see warnings and precautions (5.1)]. in patients with hypersensitivity to tranexamic acid or any of the ingredients [see warnings and precautions (5.4)]. 8.1 pregnancy risk summary available data from published studies, case series and case reports with tranexamic acid use in pregnant women in the second and third trimester and at the time of delivery have not clarified whether there is a drug-associated risk of miscarriage or adverse maternal or fetal outcomes. there are 2 (0.02%) infant cases with structural abnormalities that resulted in death when tranexamic acid was used during conception or the first trimester of pregnancy; however, due to other confounding factors the risk of major birth defects with use of tranexamic acid during pregnancy is not clear. tranexamic acid is known to pass the placenta and appears in cord blood at concentrations approximately equal to maternal concentration (see data). reproduction studies performed in mice, rats, and rabbits have not revealed any adverse effects on the fetus due to tranexamic acid administered during organogenesis. doses examined were multiples of up to 3 times (mouse), 6 times (rat), and 3 times (rabbit) the maximum human dose based on body surface area in the mouse, rat, and rabbit, respectively (see data). the estimated background risk for major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in the clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. it is not known whether tranexamic acid use in pregnant women may cause a drug-associated risk of miscarriage or adverse maternal or fetal outcomes. for decisions regarding the use of tranexamic acid during pregnancy, the potential risk of tranexamic acid administration on the fetus should always be considered along with the mother’s clinical need for tranexamic acid; an accurate risk-benefit evaluation should drive the treating physician's decision. data human data tranexamic acid passes through the placenta. the concentration in cord blood after an intravenous injection of 10 mg/kg to pregnant women is about 30 mg/l, as high as in the maternal blood. there were 13 clinical studies that described fetal and/or neonatal functional issues such as low apgar score, neonatal sepsis, cephalohematoma and 9 clinical studies that discussed alterations to growth including low birth weight and preterm birth at 22 to 36 weeks of gestation in fetuses and infants exposed to tranexamic acid in-utero. animal data in embryo-fetal development studies, tranexamic acid was administered to pregnant mice from gestation day (gd) 6 through gd 12 and rats from gd 9 through gd 14 at daily doses of 0.3 or 1.5 g/kg. there was no evidence of adverse developmental outcomes in mice and rats at multiple of 3 and 6 times the maximum recommended human dose based on body surface area in the mouse and rat, respectively. in rabbits, tranexamic acid was administered intravenously at doses of 50, 100, or 200 mg/kg/day or orally at doses of 100, 200, or 400 mg/kg/day from gd 6 through gd 18. there was no evidence of adverse developmental outcomes at dose multiples of 2 or 3 times, respectively, the maximum recommended human dose based on body surface area. intravenous doses of 200 mg/kg/day showed slightly retarded weight gain in pregnant rabbits. 8.2 lactation risk summary published literature reports the presence of tranexamic acid in human milk. there are no data on the effects of tranexamic acid on the breastfed child or the effects on milk production. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for tranexamic acid and any potential adverse effects on the breastfed child from tranexamic acid or from the underlying maternal condition. 8.3 females and males of reproductive potential contraception concomitant use of tranexamic acid, which is an antifibrinolytic, with hormonal contraceptives may increase the risk for thromboembolic adverse reactions. advise patients to use an effective alternative (nonhormonal) contraceptive method [see warnings and precautions (5.1), drug interactions (7.1)]. 8.4 pediatric use there are limited data concerning the use of tranexamic acid in pediatric patients with hemophilia who are undergoing tooth extraction. the limited data suggest that there are no significant pharmacokinetic differences between adults and pediatric patients. 8.5 geriatric use clinical studies of tranexamic acid did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. this drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function [see dosage and administration (2.2), clinical pharmacology (12.3)]. 8.6 renal impairment reduce the dosage of tranexamic acid in patients with renal impairment, based on the patient’s serum creatinine [see dosage and administration (2.2), clinical pharmacology (12.3)].

Marekani - Kiingereza - NLM (National Library of Medicine)

ani pharmaceuticals, inc. - tranexamic acid (unii: 6t84r30kc1) (tranexamic acid - unii:6t84r30kc1) - tranexamic acid tablets are indicated for the treatment of cyclic heavy menstrual bleeding in females of reproductive potential [see clinical studies (14)]. tranexamic acid tablets are contraindicated in females of reproductive potential who are [see warnings and precautions (5.1)]: tranexamic acid tablets are contraindicated in females with reproductive potential with known hypersensitivity to tranexamic acid [see warnings and precautions (5.2) and adverse reactions (6.1)]. risk summary tranexamic acid tablets are not indicated for use in pregnant women. there are no available data on tranexamic acid use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. tranexamic acid crosses the placenta. animal reproduction studies have not identified adverse developmental outcomes with oral administration of tranexamic acid to pregnant rats at doses up to 4 times the recommended human dose (see data) . in the us general population, the

Marekani - Kiingereza - NLM (National Library of Medicine)

armas pharmaceuticals inc. - tranexamic acid (unii: 6t84r30kc1) (tranexamic acid - unii:6t84r30kc1) - tranexamic acid injection is indicated in patients with hemophilia for short-term use (2 to 8 days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. tranexamic acid injection is contraindicated: - in patients with subarachnoid hemorrhage. anecdotal experience indicates that cerebral edema and cerebral infarction may be caused by tranexamic acid injection in such patients. - in patients with active intravascular clotting[see warnings and precautions(5.1 )] . - in patients with hypersensitivity to tranexamic acid or any of the ingredients[see warnings and precautions(5.4 )] . risk summary available data from published studies, case series and case reports with tranexamic acid use in pregnant women in the second and third trimester and at the time of delivery have not clarified whether there is a drug-associated risk of miscarriage or adverse maternal or fetal outcomes. there are 2 (0.02%) infant cases with structural abnormalities that result

Marekani - Kiingereza - NLM (National Library of Medicine)

bryant ranch prepack - tranexamic acid (unii: 6t84r30kc1) (tranexamic acid - unii:6t84r30kc1) - tranexamic acid tablets are indicated for the treatment of cyclic heavy menstrual bleeding in females of reproductive potential [see clinical studies (14)] tranexamic acid tablets are contraindicated in females of reproductive potential who are [see warnings and precautions (5.1)] : - using combined hormonal contraception - known to have any of the following conditions: - active thromboembolic disease (e.g., deep vein thrombosis, pulmonary embolism, or cerebral thrombosis) - a history of thrombosis or thromboembolism, including retinal vein or artery occlusion - an intrinsic risk of thrombosis or thromboembolism (e.g., thrombogenic valvular disease, thrombogenic cardiac rhythm disease, or hypercoagulopathy) tranexamic acid tablets are contraindicated in females with reproductive potential with known hypersensitivity to tranexamic acid [see warnings and precautions (5.2) and adverse reactions (6.1)]. risk summary tranexamic acid tablets are not indicated for use in pregnant women. there are no available data

Marekani - Kiingereza - NLM (National Library of Medicine)

bryant ranch prepack - tranexamic acid (unii: 6t84r30kc1) (tranexamic acid - unii:6t84r30kc1) - tranexamic acid tablets are indicated for the treatment of cyclic heavy menstrual bleeding in females of reproductive potential [see clinical studies (14)] tranexamic acid tablets are contraindicated in females of reproductive potential who are [see warnings and precautions (5.1)] : - using combined hormonal contraception - known to have any of the following conditions: - active thromboembolic disease (e.g., deep vein thrombosis, pulmonary embolism, or cerebral thrombosis) - a history of thrombosis or thromboembolism, including retinal vein or artery occlusion - an intrinsic risk of thrombosis or thromboembolism (e.g., thrombogenic valvular disease, thrombogenic cardiac rhythm disease, or hypercoagulopathy) tranexamic acid tablets are contraindicated in females with reproductive potential with known hypersensitivity to tranexamic acid [see warnings and precautions (5.2) and adverse reactions (6.1)]. risk summary tranexamic acid tablets are not indicated for use in pregnant women. there are no available data on tranexamic acid tablets use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. tranexamic acid crosses the placenta. animal reproduction studies have not identified adverse developmental outcomes with oral administration of tranexamic acid to pregnant rats at doses up to 4 times the recommended human dose (see data) . in the us general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. data animal data in a rat embryo-fetal developmental toxicity study, tranexamic acid had no adverse effects on embryo-fetal development when administered during the period of organogenesis (from gestation days 6 through 17) at twice daily doses of 0, 150, 375, and 750 mg/kg (1, 2 and 4 times the recommended human oral dosage of 3900 mg/day based on body surface area (mg/m2 )). in a perinatal-postnatal developmental toxicity study in rats administered tranexamic acid from gestation day 6 through postnatal day 20 at twice daily doses of 0, 150, 375, and 750 mg/kg, no significant adverse effects on maternal behavior or body weight were observed, and no significant effects on pup viability, body weight, developmental milestones or adult fertility were observed. it was concluded that the no-observed-effect-level (noel) for this study was 1500 mg/kg/day in both f0 and f1 generations, which is equivalent to 4 times the recommended human oral dose of 3900 mg/day based on body surface area (mg/m2 ). risk summary tranexamic acid is present in the mother’s milk at a concentration of about one hundredth of the corresponding serum concentration (see data). the amount of tranexamic acid a nursing infant would absorb is unknown. there are no adequate data on the effects of tranexamic acid on the breastfed infant or the effects of tranexamic acid on milk production. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for tranexamic acid tablets and any potential adverse effects on the breast-fed child from tranexamic acid tablets or from the underlying maternal condition. data human data one hour after the last dose following a 2-day treatment course in lactating women, the milk concentration of the tranexamic acid was 1% of the peak serum concentration. the safety and effectiveness of tranexamic acid tablets have been established in females of reproductive potential. efficacy is expected to be the same for post-menarchal females under the age of 17 as for those 17 years and older. tranexamic acid tablets are not indicated before menarche. tranexamic acid tablets are indicated for females of reproductive potential and are not intended for use by postmenopausal women. the effect of renal impairment on the pharmacokinetics of tranexamic acid tablets has not been studied. because tranexamic acid is primarily eliminated via the kidneys by glomerular filtration with more than 95% excreted as unchanged in urine, the recommended dosage in patients with renal impairment is lower than the recommended dosage in patients with normal renal function [see dosage and administration (2.2) and clinical pharmacology (12.3)] . the effect of hepatic impairment on the pharmacokinetics of tranexamic acid tablets has not been studied. because only a small fraction of the drug is metabolized, the recommended dosage in patients with hepatic impairment is the same as in patients with normal hepatic function [see clinical pharmacology (12.3)] .